SciClone Pharmaceuticals (Holdings) (HKSE:06600) Total Assets : HK$4,375 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Total Assets?

SciClone Pharmaceuticals (Holdings)'s Total Assets for the quarter that ended in Dec. 2023 was HK$4,375 Mil.

During the past 12 months, SciClone Pharmaceuticals (Holdings)'s average Total Assets Growth Rate was 3.70% per year. During the past 3 years, the average Total Assets Growth Rate was -1.10% per year. During the past 5 years, the average Total Assets Growth Rate was 15.20% per year.

During the past 7 years, SciClone Pharmaceuticals (Holdings)'s highest 3-Year average Total Assets Growth Rate was 28.00%. The lowest was -1.10%. And the median was 25.90%.

Total Assets is connected with ROA %. SciClone Pharmaceuticals (Holdings)'s annualized ROA % for the quarter that ended in Dec. 2023 was 24.05%. Total Assets is also linked to Revenue through Asset Turnover. SciClone Pharmaceuticals (Holdings)'s Asset Turnover for the quarter that ended in Dec. 2023 was 0.38.

SciClone Pharmaceuticals (Holdings) Total Assets Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Total Assets Chart

SciClone Pharmaceuticals (Holdings) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

2,053.94

3,417.18

4,974.62

4,824.66

4,375.39

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Assets	Get a 7-Day Free Trial						4,974.62	5,075.73	4,824.66	4,571.03	4,375.39

SciClone Pharmaceuticals (Holdings) Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

SciClone Pharmaceuticals (Holdings)'s Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	3571.261	+	804.128
	=	4,375

SciClone Pharmaceuticals (Holdings)'s Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	3571.261	+	804.128
	=	4,375

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Total Assets Explanation

Total Assets is connected with ROA %.

SciClone Pharmaceuticals (Holdings)'s annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	1075.664	/	( (4571.031	+	4375.389)	/ 2 )
	=	1075.664	/	4473.21
	=	24.05 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

SciClone Pharmaceuticals (Holdings)'s Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	1697.854	/	( (4571.031	+	4375.389)	/ 2 )
=	1697.854	/	4473.21
=	0.38

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

SciClone Pharmaceuticals (Holdings) Total Assets Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Total Assets

Traded in Other Exchanges

N/A

Address

381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN

Website

https://www.sciclone.com

SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Zhao Hong	2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang	2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited	2501 Other
Ascendent Capital Partners Ii Gp Limited	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p.	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p.	2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited	2101 Beneficial owner
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Bank Of China Limited	2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited	2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines